ArticleEuropean journal of nuclear medicine and molecular imaging2014
A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Prognostic usefulness of planarJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Trial
- Cardiac sympathetic nerve activity following mitral transcatheter edge-to-edge repair verified byHeart and vessels · 2026Article
- Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.European journal of nuclear medicine and molecular imaging · 2026Article
- Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine.European journal of nuclear medicine and molecular imaging · 2026Article
- Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- JCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia.Journal of arrhythmia · 2024Article
- Cardiac Sympathetic Nerve Function in Patients with Severe Aortic Stenosis Prior and After Transcatheter Aortic Valve Implantation: Evaluation by 5-Year Risk Model.Annals of nuclear cardiology · 2024Article
- Cardiac sympathetic activity and relationship to cardiac events and left ventricular reverse remodeling in patients with non-ischemic dilated cardiomyopathy.Annals of nuclear medicine · 2023Article
- Three-Dimensional Heart Segmentation and Absolute Quantitation of CardiacAnnals of nuclear cardiology · 2023Article
- Validation of a Five-Year Prognostic Model UsingAnnals of nuclear cardiology · 2023Article
- Reclassification of Heart Failure with Preserved Ejection Fraction Following Cardiac Sympathetic Nervous System Activation: A New Cutoff Value of 58.Tomography (Ann Arbor, Mich.) · 2022Observational
- CardiacPharmaceuticals (Basel, Switzerland) · 2022Review
- Autopsy Validation of the Diagnostic Accuracy ofNeurology · 2022Article
- Machine learning-based risk model usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Nuclear Cardiology Data Analyzed Using Machine Learning.Annals of nuclear cardiology · 2022Review
- Convolutional neural network-based automatic heart segmentation and quantitation inEJNMMI research · 2021Article
- Paradoxical Prognostic Implications of Visceral Adiposity for Lethal Cardiac Events in Association with Impaired Cardiac Sympathetic Innervation in Chronic Heart Failure.Annals of nuclear cardiology · 2020Article
- Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Observational
- Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure.European heart journal. Cardiovascular Imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrediction of mortality risk is important in the management of chronic heart failure (CHF). The aim of this study was to create a prediction model for 5-year cardiac death including assessment of cardiac sympathetic innervation using data from a multicenter cohort study in Japan.
methodsThe original pooled database consisted of cohort studies from six sites in Japan. A total of 933 CHF patients who underwent (123)I-metaiodobenzylguanidine (MIBG) imaging and whose 5-year outcomes were known were selected from this database. The late MIBG heart-to-mediastinum ratio (HMR) was used for quantification of cardiac uptake. Cox proportional hazard and logistic regression analyses were used to select appropriate variables for predicting 5-year cardiac mortality. The formula for predicting 5-year mortality was created using a logistic regression model.
resultsDuring the 5-year follow-up, 205 patients (22 %) died of a cardiac event including heart failure death, sudden cardiac death and fatal acute myocardial infarction (64 %, 30 % and 6 %, respectively). Multivariate logistic analysis selected four parameters, including New York Heart Association (NYHA) functional class, age, gender and left ventricular ejection fraction, without HMR (model 1) and five parameters with the addition of HMR (model 2). The net reclassification improvement analysis for all subjects was 13.8 % (p < 0.0001) by including HMR and its inclusion was most effective in the downward reclassification of low-risk patients. Nomograms for predicting 5-year cardiac mortality were created from the five-parameter regression model.
conclusionCardiac MIBG imaging had a significant additive value for predicting cardiac mortality. The prediction formula and nomograms can be used for risk stratifying in patients with CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.